Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could patient tissue samples unlock new treatments for gut diseases?

NCT ID NCT07782203

Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This study aims to create a collection of tissue and blood samples from people with digestive cancers or inflammatory bowel disease (IBD). Researchers will use these samples to build lab models that mimic how tumors grow and respond to treatments. The goal is to better understand these diseases and test new therapies in a personalized way. Participants will donate samples during routine procedures like endoscopy or surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Collection of tissue and blood samples (biopsy) for research
What this could lead to
If successful, this collection could help scientists build realistic lab models of digestive cancers and IBD, potentially speeding up the discovery of new treatments and personalized medicine approaches.
What could go wrong
This is an early-stage research effort, not a treatment trial. The samples may not always be suitable for lab models, and any future therapies are years away.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with IBD and for whom a digestive endoscopy +/- echo-endoscopy or gastrointestinal tract surgery is planned as part of care. * Diagnosed with digestive tract cancer on IBD and for whom a digestive endoscopy +/- echo-endoscopy or gastrointestinal tract surgery is planned as part of care. * Diagnosed with digestive cancer (esophagus, stomach, colon/rectum) and for whom a digestive endoscopy +/- echo-endoscopy or gastrointestinal tract surgery is planned as part of care. * Diagnosed with Barrett's esophagus and for whom a digestive endoscopy +/- echo-endoscopy or gastrointestinal tract surgery is planned as part of care Exclusion Criteria: * All other

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Barrett's esophagus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Barrett esophagus digestive system cancer digestive system neoplasm inflammatory bowel disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastrointestinal cancer IBD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpitaux Universitaires de Strasbourg

    RECRUITING

    Strasbourg, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.